Immune Responses to HBV Vaccine in People Living with HIV (PLWHs) Who Achieved Successful Treatment: A Prospective Cohort Study

Background: Understanding immune responses after HBV vaccination is important to prevent HBV infection in PLWH and to achieve successful treatment. Methods: Thirty-two PLWHs with CD4+ cell count > 350 cells/µL and HIV RNA < 200 copies/mL were vaccinated with 20 µg of HBV vaccine at weeks 0, 4, and 24 in this prospective study. We measured total HIV DNA levels, HBsAb titers and HBsAg-specific T-cell responses during follow-up time. Results: All patients achieved protective HBsAb titer after immunization. The magnitude of the IFN-r and TNF-a response to HBsAg was 22.0 (IQR: 6.5–65.0) and 106.50 (IQR: 58.5–203.0) spot-forming cells (SFC)/105 PBMC, respectively at week 0. The level of IFN-r secreted at weeks 12 and weeks 36 to 48 was comparable with that at week 0. However, IFN-r response was higher at weeks 12 than that at weeks 36 to 48 (p = 0.02). The level of TNF-a secreted at weeks 12 was higher than that at week 0 (p < 0.001). Total HIV DNA levels were 2.76 (IQR: 2.47–3.07), 2.77 (IQR: 2.50–3.09), 2.77 (IQR: 2.41–2.89) log10 copies/106 PBMCs at weeks 0, 12, 36 to 48, respectively. No correlation was observed between IFN-r and TNF-a levels and HBsAb titer as well as total HIV DNA levels after immunization. Conclusion: Humoral immunity was satisfactory, but cellular immunity and decline in HIV reservoir were not optimal after HBV vaccine immunization in these patients.

[1]  A. De Vito,et al.  Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance Test from a Multicenter Italian Cohort , 2022, Journal of personalized medicine.

[2]  Hao Wu,et al.  Immune Response to Hepatitis B Virus Vaccine Among People Living With HIV: A Meta-Analysis , 2021, Frontiers in Immunology.

[3]  W. Cao,et al.  Naïve CD4+ cell counts significantly decay and high HIV RNA levels contribute to immunological progression in long-term non-progressors infected with HIV by blood products: a cohort study , 2021, BMC immunology.

[4]  Yunda Huang,et al.  Therapeutic prediction of HIV-1 DNA decay: a multicenter longitudinal cohort study , 2020, BMC Infectious Diseases.

[5]  S. Lewin,et al.  Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure? , 2020, Journal of acquired immune deficiency syndromes.

[6]  H. Kwon,et al.  Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients. , 2020, Vaccine.

[7]  M. Maini,et al.  Shared immunotherapeutic approaches in HIV and hepatitis B virus: combine and conquer. , 2020, Current opinion in HIV and AIDS.

[8]  C. Flexner,et al.  Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. , 2019, The lancet. HIV.

[9]  K. Sherman,et al.  Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV , 2019, Current HIV/AIDS Reports.

[10]  Masashi Suzuki,et al.  Interaction Between Regulatory T Cells and Antibody-Producing B Cells for Immune Responses at the Upper Respiratory Mucosa Against Nontypeable Haemophilus influenzae: In Vitro Assay Model , 2019, The Annals of otology, rhinology, and laryngology.

[11]  L. Sticchi,et al.  Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course. , 2018, AIDS research and human retroviruses.

[12]  R. Chaiwarith,et al.  Hepatitis B Vaccination Induced TNF-α- and IL-2-Producing T Cell Responses in HIV− Healthy Individuals Higher than in HIV+ Individuals Who Received the Same Vaccination Regimen , 2018, Journal of immunology research.

[13]  Noele P. Nelson,et al.  Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices , 2018, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[14]  F. Chiodi,et al.  Hepatitis B Virus Vaccination in HIV-1-Infected Young Adults: A Tool to Reduce the Size of HIV-1 Reservoirs? , 2018, Front. Immunol..

[15]  S. Lewin,et al.  HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment , 2017, AIDS.

[16]  C. Marano,et al.  The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience , 2017, Expert review of vaccines.

[17]  A. Facciolà,et al.  Response to anti-HBV vaccine and 10-year follow-up of antibody levels in healthcare workers. , 2016, Public health.

[18]  C. Rouzioux,et al.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications , 2016, Clinical Microbiology Reviews.

[19]  B. McMahon,et al.  A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen. , 2016, The Journal of infectious diseases.

[20]  F. Carrat,et al.  Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. , 2015, The Lancet. Infectious diseases.

[21]  L. Dijksman,et al.  Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection , 2014, AIDS.

[22]  P. Böelle,et al.  Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  R. D. de Man,et al.  Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. , 2013, Vaccine.

[24]  Zong-tang Sun,et al.  Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. , 2011, Vaccine.

[25]  W. Borkowsky,et al.  Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. , 2009, The Journal of infectious diseases.

[26]  K. H. Hullsiek,et al.  Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. , 2009, Vaccine.

[27]  C. Mengoli,et al.  Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. , 2009, Vaccine.

[28]  W. Jilg,et al.  Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. , 2006, Vaccine.

[29]  G. Leroux-Roels,et al.  A comparison of two commercial recombinant vaccines for hepatitis B in adolescents. , 2000, Vaccine.

[30]  R. Haubrich,et al.  Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. , 2000, The Journal of infectious diseases.